ClinConnect ClinConnect Logo
Search / Trial NCT05367518

Colonisation Efficacy of Oral Probiotic Fast Melt Powder

Launched by BLIS TECHNOLOGIES LIMITED · May 5, 2022

Trial Information

Current as of June 25, 2025

Unknown status

Keywords

Streptococcus Salivarius K12 Oral Probiotic Fast Melt Powder

ClinConnect Summary

This is a double-blind, randomized controlled study with no cross over to evaluate the colonization efficacy of fast melt powders containing a commercially available probiotic bacterium Streptococcus salivarius K12.

Participants will be randomly assigned to one of the 2 groups consuming Fast Melt powder containing two different doses of Streptococcus salivarius K12 over a seven day period. Saliva samples will be collected at predetermined time points pre and post intervention. Colonization efficacy will be determined by enumerating the probiotic in the saliva samples using standard microbi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. In general good health 18 - 80 years of age.
  • 2. Practice good oral hygiene.
  • Exclusion Criteria:
  • 1. Have a history of autoimmune disease or are immunocompromised.
  • 2. Are on concurrent antibiotic therapy or regular antibiotic use within last 1 week
  • 3. History of allergy (e.g. dairy).

About Blis Technologies Limited

Blis Technologies Limited is an innovative biotechnology company focused on the development and commercialization of advanced microbial therapies for a range of health applications. With a commitment to harnessing the power of beneficial bacteria, the company specializes in research and clinical trials aimed at enhancing oral and systemic health through its proprietary probiotic formulations. Leveraging cutting-edge technology and a strong scientific foundation, Blis Technologies Limited strives to improve patient outcomes and contribute to the growing field of microbiome research, positioning itself as a leader in the development of safe and effective therapeutic solutions.

Locations

Dunedin, Otago, New Zealand

Patients applied

0 patients applied

Trial Officials

John D Hale, PhD

Study Director

Blis Technologies Ltd, Dunedin, New Zealand

John R Tagg, PhD

Principal Investigator

Blis Technologies Ltd, Dunedin, New Zealand

Rohit Jain, PhD

Principal Investigator

Blis Technologies Ltd, Dunedin, New Zealand

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials